{"id":"W3185740766","doi":"10.1016/s0140-6736(21)01380-5","title":"Tocilizumab in COVID-19 therapy: who benefits, and how?","year":2021,"lang":"en","type":"letter","venue":"The Lancet","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Toronto General Hospital; McGill University; University Health Network","funders":"","keywords":"Medicine; Tocilizumab; Clinical endpoint; Pneumonia; Thrombosis; Coronavirus disease 2019 (COVID-19); Internal medicine; Intensive care unit; Randomized controlled trial; Venous thrombosis; Intensive care medicine; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.03191263,0.001184624,0.004323425,0.001668941,0.00466796,0.007975078,0.003032713,0.06998882,0.0117821],"category_scores_gemma":[0.09793898,0.00114702,0.002469824,0.002092804,0.006443427,0.008231666,0.003070978,0.04035193,0.00939567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.009062173,"about_ca_system_score_gemma":0.01578896,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01018779,"about_ca_topic_score_gemma":0.02124378,"domain_scores_codex":[0.9715638,0.01475126,0.004103164,0.001482897,0.006067,0.002031992],"domain_scores_gemma":[0.8978083,0.07285005,0.006176869,0.002186099,0.009318756,0.01165995],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004806882,0.0000342239,0.0005766999,0.0004274259,0.0001006818,0.0004375149,0.0000817792,0.00003424794,0.0001813451,0.005675874,0.9676493,0.02432021],"study_design_scores_gemma":[0.001395204,0.0001923516,0.001529406,0.003020738,0.000274889,0.0008022745,0.0004051853,0.0002657337,0.0002596894,0.03631966,0.9554152,0.0001195706],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.0001391877,0.008386123,0.00004086504,0.9780204,0.01148449,0.00001035885,0.0001160126,0.00001050063,0.001792069],"genre_scores_gemma":[0.00204764,0.004933188,0.0002268702,0.9475648,0.04297375,0.00005113829,0.00004927024,0.00002259787,0.002130856],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.06998882,"threshold_uncertainty_score":0.1687722,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1607272023535913,"score_gpt":0.4237469090042861,"score_spread":0.2630197066506948,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}